<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; WCRX</title>
	<atom:link href="http://www.stockbloghub.com/tag/wcrx/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MYL) Mylan Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071</link>
		<comments>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071#comments</comments>
		<pubDate>Tue, 06 Dec 2011 00:54:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88071</guid>
		<description><![CDATA[Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food &#38; Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and Abbott Labs&#8216; (ABT) Norvir for the treatment of HIV/AIDS. The fixed drug combination has been pre-qualified to be used in treatment of experienced patients by the World Health Organization (WHO). It can also be used in combination with other antiretroviral (ARV) agents and will be eligible for purchase in certain developing countries. The drug was approved through the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR). The drug will boost Mylan’s already strong portfolio of ARV’s in India. In a separate development, Mylan announced that Warner Chilcott Company (WCRX) filed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145</link>
		<comments>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:26:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82145</guid>
		<description><![CDATA[We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks Consensus Estimate by a penny and the year-ago earnings by 18 cents. Earnings were bolstered by higher revenues. Revenues for the quarter climbed 24% to $1.08 billion, beating the Zacks Consensus Estimate of $992 million. Revenues went up mainly due to increased generic and branded drug sales. Following the better-than-expected second quarter results, Watson Pharma increased its 2011 earning guidance range to $4.25-$4.50 per share from $3.95-$4.20. We note that the company enjoys a strong position in the generic pharmaceutical market. At the end of 2010, Watson Pharma had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WCRX) Warner Chilcott Announces Change in Leadership of Research &amp; Development Division</title>
		<link>http://www.stockbloghub.com/2011/07/01/wcrx-warner-chilcott-announces-change-in-leadership-of-research-development-division/78147</link>
		<comments>http://www.stockbloghub.com/2011/07/01/wcrx-warner-chilcott-announces-change-in-leadership-of-research-development-division/78147#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:44:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[WCRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78147</guid>
		<description><![CDATA[Warner Chilcott (WCRX) recently announced that there will be a change at the helm of its research &#38; development (R&#38;D) division from the beginning of next year. The need for change arose following the decision of Warner Chilcott’s incumbent R&#38;D chief, Dr. Fawzi, to resign. Warner Chilcott targets women&#8217;s healthcare, gastroenterology, dermatology and urology markets in the US and Western Europe. Dr. Fawzi is expected to serve the company in his present capacity until the end of 2011. Warner Chilcott has formed a committee to oversee operations of the R&#38;D division until the unit gets a new head. The committee will be headed by Dr. John King, a member of Warner Chilcott’s Board of Directors since 2005. Dr. Fawzi has been with Warner Chilcott since October 2009 when the company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/wcrx-warner-chilcott-announces-change-in-leadership-of-research-development-division/78147/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals  and Columbia Laboratories Drug&#8217;s NDA Accepted</title>
		<link>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-and-columbia-laboratories-drugs-nda-accepted/77887</link>
		<comments>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-and-columbia-laboratories-drugs-nda-accepted/77887#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:59:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBRX]]></category>
		<category><![CDATA[Columbia Laboratories Inc]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77887</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) along with Columbia Laboratories Inc. (CBRX) recently announced that the latter’s New Drug Application (NDA) for Prochieve (progesterone gel) has been accepted by the US Food and Drug Administration (FDA). The companies are looking to get Prochieve approved for the reduction of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. However, Columbia Labs has withdrawn its request for priority review of the drug, following which the FDA has set a target date of February 26, 2012 for Prochieve. In July last year, Watson Pharma had acquired the US rights to Columbia Labs’ products Prochieve and Crinone. According to the purchase and collaboration agreement, following the FDA’s acceptance of the Prochieve NDA, Watson Pharma will have to make a $5 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-and-columbia-laboratories-drugs-nda-accepted/77887/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917</link>
		<comments>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:02:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68917</guid>
		<description><![CDATA[We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago earnings. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. For full year 2010, Watson Pharma earned $3.42 per share (up 12.5%) on revenues of $3.6 billion (up 28%). The Zacks Consensus Estimate for 2010 was $3.42 per share on revenues of $3.5 billion. We believe that the company’s cost saving initiative and new product launches, both branded and generic, will help drive growth. We have raised our ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WCRX) Warner Chilcott Earns US Food and Drug Administration Approval for Actonel</title>
		<link>http://www.stockbloghub.com/2010/10/12/wcrx-warner-chilcott-earns-us-food-and-drug-administration-approval-for-actonel/55003</link>
		<comments>http://www.stockbloghub.com/2010/10/12/wcrx-warner-chilcott-earns-us-food-and-drug-administration-approval-for-actonel/55003#comments</comments>
		<pubDate>Wed, 13 Oct 2010 01:45:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[WCRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55003</guid>
		<description><![CDATA[Warner Chilcott plc (WCRX) recently announced that the US Food and Drug Administration (FDA) approved a next-generation version of its postmenopausal osteoporosis treatment Actonel. The company plans to market this drug as Atelvia in the US and launch it commercially early next year. The FDA nod for Atelvia came after the regulatory body extended the review period of the drug (in July) by three months. The Prescription Drug User Fee Act date was set for October 24, 2010, with the FDA asking for more time to review additional data on the candidate, submitted by the company on the regulatory body’s request. Actonel is marketed worldwide as a treatment of postmenopausal osteoporosis. The drug lost patent exclusivity in Canada in the first quarter of 2010 and will lose exclusivity in Europe ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/12/wcrx-warner-chilcott-earns-us-food-and-drug-administration-approval-for-actonel/55003/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WCRX) Warner Chilcott &#8211; Revenues Nearly Triple</title>
		<link>http://www.stockbloghub.com/2010/03/18/wcrx-warner-chilcott-revenues-nearly-triple/30732</link>
		<comments>http://www.stockbloghub.com/2010/03/18/wcrx-warner-chilcott-revenues-nearly-triple/30732#comments</comments>
		<pubDate>Thu, 18 Mar 2010 21:14:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[WCRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30732</guid>
		<description><![CDATA[Warner Chilcott plc (WCRX) profits are up sharply after a recent acquisition. Analysts are projecting nice growth and the stock is still trading at a nice value. Company Description Warner Chilcott makes pharmaceuticals for gastroenterology, women&#8217;s healthcare, dermatology and urology. The company distributes is products Western Europe and North America. Revenues Nearly Triple Warner Chilcott reported earnings results on Mar 1 that showed revenues of $686 million, up 183% from one year ago. The majority of the increase is due to the acquisition of a Procter &#38; Gamble business unit. Earnings per shares came in at 70 cents, 13 cents ahead of expectations. Estimate Revisions Over the past 2 months, the full-year Zacks Consensus Estimate is up 27 cents to $3.40. This represents a growth rate of nearly 80%. Analysts ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/wcrx-warner-chilcott-revenues-nearly-triple/30732/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PG) The Procter &amp; Gamble Company Acquires Ambi Pur Brand From Sara Lee Corporation</title>
		<link>http://www.stockbloghub.com/2009/12/17/pg-the-procter-gamble-company-acquires-ambi-pur-brand-from-sara-lee-corporation/23160</link>
		<comments>http://www.stockbloghub.com/2009/12/17/pg-the-procter-gamble-company-acquires-ambi-pur-brand-from-sara-lee-corporation/23160#comments</comments>
		<pubDate>Fri, 18 Dec 2009 01:05:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Personal Products]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[WCRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23160</guid>
		<description><![CDATA[The Procter &#38; Gamble Company (PG) signed an agreement to acquire the Ambi Pur Brand from Sara Lee Corporation (SLE) for €320 million ($470 million). Ambi Pur is a leading global air care brand with several toilet care products. The company has strong a presence in Western Europe and Asia. The Ambi Pur brand generated annual sales of approximately €260 million ($355 million) for fiscal 2009. The acquisition of Ambi Pur strengthens Procter and Gamble’s global leadership business in Home Care, especially Air Care by reaching out to more consumers worldwide. This acquisition not only brings in the strong Ambi Pur brand equity, but also provides geographic presence particularly in Europe and Asia. Moreover, the Ambi Pur brand acquisition adds high-performance products and new technologies to the company’s current Air ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/pg-the-procter-gamble-company-acquires-ambi-pur-brand-from-sara-lee-corporation/23160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WCRX) Warner Chilcott Limited &#8211; boosted earnings guidance following the excellent quarterly results</title>
		<link>http://www.stockbloghub.com/2008/12/23/warner-chilcott-limited-boosted-earnings-guidance-following-the-excellent-quarterly-results/1820</link>
		<comments>http://www.stockbloghub.com/2008/12/23/warner-chilcott-limited-boosted-earnings-guidance-following-the-excellent-quarterly-results/1820#comments</comments>
		<pubDate>Tue, 23 Dec 2008 22:35:44 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[VitalStocks]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[WCRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1820</guid>
		<description><![CDATA[Warner Chilcott Limited (WCRX) is raising guidance, amid economic turmoil, based an excellent quarterly results. Analysts are raising their forecasts and the stock was just added to a major index. Company Description Warner Chilcott is a leading specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products. The drugs are for women&#8217;s healthcare and dermatology in the United States. The company prides itself in its proven product development capabilities, coupled with the ability to execute acquisitions and in-licensing transactions and develop partnerships. Solid Quarterly Results Warner Chilcott announced quarterly results on Nov 10 which included earnings per share of 16 cents, 8 times higher than the same quarter last year. Revenues rose 2.4% to $232 million on a year-over-year basis. The strong numbers were driven by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/12/23/warner-chilcott-limited-boosted-earnings-guidance-following-the-excellent-quarterly-results/1820/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

